TH‐C‐350‐03: A Dosimetric Validation of RapidArc Treatment Plans for 5 Treatment Sites

Research output: Contribution to journalArticleAcademicpeer-review

Abstract

Purpose: To compare calculated and delivered dose distributions from RapidArc™ (a form of volumetric modulated arc therapy, Varian Medical Systems). RapidArc is a novel approach for delivering single arc therapy in less than 2 minutes, while achieving dose distributions comparable to current IMRT. We report the first detailed dosimetric validation for 5 different tumour sites with RapidArc plans. Method and Materials: Clinical RapidArc plans were generated with a pre‐clinical version for single cases with glioblastoma multiforme, multiple brain metastases, nasopharynx‐, oropharynx‐ and pancreas carcinoma. All five plans were delivered with a Varian Linac and measured in a solid water phantom for 5 coronal planes, 2 cm separated, using double Gafchromic®EBT films. Plans were also measured using ionisation chamber arrays (MatriXX). Measured and calculated dose distributions were compared using 2D gamma evaluation with limits of 2mm and 3.5% (of typical PTV dose in phantom). Results: All 25 film measurements showed high agreement with calculations, with a mean gamma of 0.29 and on average 1% (maximum 3%) of the film surface exceeding a gamma of 1.0. Relatively strong spatial dose modulations could be measured, within 95–107% dose range in the PTV, which were not completely predicted by calculations. This could lead to local dose changes >3% when changing a plane by 2mm. MatriXX measurements corresponded better with dose calculations than film measurements, which may be due to the limited resolution of 7.6mm of MatriXX. Conclusion: RapidArc accurately delivers the planned dose distributions. Film measurements may be preferred for dosimetric verification as more dose modulation is detectable than with ionisation array measurements. A “2.5D” gamma evaluation taking into account multiple adjacent dose planes would show better agreement for film dosimetry. Our results indicate that RapidArc can be introduced into clinical practice. Conflict of Interest: Research was a collaboration with Varian Medical Systems.

Original languageEnglish
Number of pages1
JournalMedical Physics
Volume35
Issue number6
DOIs
Publication statusPublished - 1 Jan 2008

Cite this

@article{340880bfc8514fa9b150f1f530ccb30e,
title = "TH‐C‐350‐03: A Dosimetric Validation of RapidArc Treatment Plans for 5 Treatment Sites",
abstract = "Purpose: To compare calculated and delivered dose distributions from RapidArc™ (a form of volumetric modulated arc therapy, Varian Medical Systems). RapidArc is a novel approach for delivering single arc therapy in less than 2 minutes, while achieving dose distributions comparable to current IMRT. We report the first detailed dosimetric validation for 5 different tumour sites with RapidArc plans. Method and Materials: Clinical RapidArc plans were generated with a pre‐clinical version for single cases with glioblastoma multiforme, multiple brain metastases, nasopharynx‐, oropharynx‐ and pancreas carcinoma. All five plans were delivered with a Varian Linac and measured in a solid water phantom for 5 coronal planes, 2 cm separated, using double Gafchromic{\circledR}EBT films. Plans were also measured using ionisation chamber arrays (MatriXX). Measured and calculated dose distributions were compared using 2D gamma evaluation with limits of 2mm and 3.5{\%} (of typical PTV dose in phantom). Results: All 25 film measurements showed high agreement with calculations, with a mean gamma of 0.29 and on average 1{\%} (maximum 3{\%}) of the film surface exceeding a gamma of 1.0. Relatively strong spatial dose modulations could be measured, within 95–107{\%} dose range in the PTV, which were not completely predicted by calculations. This could lead to local dose changes >3{\%} when changing a plane by 2mm. MatriXX measurements corresponded better with dose calculations than film measurements, which may be due to the limited resolution of 7.6mm of MatriXX. Conclusion: RapidArc accurately delivers the planned dose distributions. Film measurements may be preferred for dosimetric verification as more dose modulation is detectable than with ionisation array measurements. A “2.5D” gamma evaluation taking into account multiple adjacent dose planes would show better agreement for film dosimetry. Our results indicate that RapidArc can be introduced into clinical practice. Conflict of Interest: Research was a collaboration with Varian Medical Systems.",
author = "W. Verbakel and S. Senan and F. Lagerwaard and D. Hoffmans and J. Cuijpers and B. Slotman",
year = "2008",
month = "1",
day = "1",
doi = "10.1118/1.2962828",
language = "English",
volume = "35",
journal = "Medical Physics",
issn = "0094-2405",
publisher = "AAPM - American Association of Physicists in Medicine",
number = "6",

}

TH‐C‐350‐03 : A Dosimetric Validation of RapidArc Treatment Plans for 5 Treatment Sites. / Verbakel, W.; Senan, S.; Lagerwaard, F.; Hoffmans, D.; Cuijpers, J.; Slotman, B.

In: Medical Physics, Vol. 35, No. 6, 01.01.2008.

Research output: Contribution to journalArticleAcademicpeer-review

TY - JOUR

T1 - TH‐C‐350‐03

T2 - A Dosimetric Validation of RapidArc Treatment Plans for 5 Treatment Sites

AU - Verbakel, W.

AU - Senan, S.

AU - Lagerwaard, F.

AU - Hoffmans, D.

AU - Cuijpers, J.

AU - Slotman, B.

PY - 2008/1/1

Y1 - 2008/1/1

N2 - Purpose: To compare calculated and delivered dose distributions from RapidArc™ (a form of volumetric modulated arc therapy, Varian Medical Systems). RapidArc is a novel approach for delivering single arc therapy in less than 2 minutes, while achieving dose distributions comparable to current IMRT. We report the first detailed dosimetric validation for 5 different tumour sites with RapidArc plans. Method and Materials: Clinical RapidArc plans were generated with a pre‐clinical version for single cases with glioblastoma multiforme, multiple brain metastases, nasopharynx‐, oropharynx‐ and pancreas carcinoma. All five plans were delivered with a Varian Linac and measured in a solid water phantom for 5 coronal planes, 2 cm separated, using double Gafchromic®EBT films. Plans were also measured using ionisation chamber arrays (MatriXX). Measured and calculated dose distributions were compared using 2D gamma evaluation with limits of 2mm and 3.5% (of typical PTV dose in phantom). Results: All 25 film measurements showed high agreement with calculations, with a mean gamma of 0.29 and on average 1% (maximum 3%) of the film surface exceeding a gamma of 1.0. Relatively strong spatial dose modulations could be measured, within 95–107% dose range in the PTV, which were not completely predicted by calculations. This could lead to local dose changes >3% when changing a plane by 2mm. MatriXX measurements corresponded better with dose calculations than film measurements, which may be due to the limited resolution of 7.6mm of MatriXX. Conclusion: RapidArc accurately delivers the planned dose distributions. Film measurements may be preferred for dosimetric verification as more dose modulation is detectable than with ionisation array measurements. A “2.5D” gamma evaluation taking into account multiple adjacent dose planes would show better agreement for film dosimetry. Our results indicate that RapidArc can be introduced into clinical practice. Conflict of Interest: Research was a collaboration with Varian Medical Systems.

AB - Purpose: To compare calculated and delivered dose distributions from RapidArc™ (a form of volumetric modulated arc therapy, Varian Medical Systems). RapidArc is a novel approach for delivering single arc therapy in less than 2 minutes, while achieving dose distributions comparable to current IMRT. We report the first detailed dosimetric validation for 5 different tumour sites with RapidArc plans. Method and Materials: Clinical RapidArc plans were generated with a pre‐clinical version for single cases with glioblastoma multiforme, multiple brain metastases, nasopharynx‐, oropharynx‐ and pancreas carcinoma. All five plans were delivered with a Varian Linac and measured in a solid water phantom for 5 coronal planes, 2 cm separated, using double Gafchromic®EBT films. Plans were also measured using ionisation chamber arrays (MatriXX). Measured and calculated dose distributions were compared using 2D gamma evaluation with limits of 2mm and 3.5% (of typical PTV dose in phantom). Results: All 25 film measurements showed high agreement with calculations, with a mean gamma of 0.29 and on average 1% (maximum 3%) of the film surface exceeding a gamma of 1.0. Relatively strong spatial dose modulations could be measured, within 95–107% dose range in the PTV, which were not completely predicted by calculations. This could lead to local dose changes >3% when changing a plane by 2mm. MatriXX measurements corresponded better with dose calculations than film measurements, which may be due to the limited resolution of 7.6mm of MatriXX. Conclusion: RapidArc accurately delivers the planned dose distributions. Film measurements may be preferred for dosimetric verification as more dose modulation is detectable than with ionisation array measurements. A “2.5D” gamma evaluation taking into account multiple adjacent dose planes would show better agreement for film dosimetry. Our results indicate that RapidArc can be introduced into clinical practice. Conflict of Interest: Research was a collaboration with Varian Medical Systems.

UR - http://www.scopus.com/inward/record.url?scp=64049103305&partnerID=8YFLogxK

U2 - 10.1118/1.2962828

DO - 10.1118/1.2962828

M3 - Article

VL - 35

JO - Medical Physics

JF - Medical Physics

SN - 0094-2405

IS - 6

ER -